冠心病影像检查成本效益综述:核医学影像的经济学评价
本文综述了冠心病影像检查的成本效益研究,重点涉及SPECT和PET心肌灌注显像。由于机构资源、操作者经验、临床场景和报销结构等因素导致数据异质性大,尚无法对每种模态得出确定性成本效益结论;结构化的多模态影像策略可能提供更高的诊断与经济价值。
要点
- SPECT或PET心肌灌注显像长期是冠心病诊治的基石。
- 数据异质性大,尚无法确定各影像模态的成本效益。
- 结构化的多模态影像策略可能兼顾临床结局与资源利用效率。
核心结论
- 现有数据尚不足以对冠心病各影像模态的成本效益得出确定性结论。
- 结构化的多模态影像策略可能提供更大的诊断与经济价值。
研究设计与样本
- 综述类文章,汇总冠心病影像检查成本效益的相关研究。
主要发现
- 数据异质性主要与机构资源、操作者经验、临床场景、医疗体系和报销结构相关。
- 多模态影像策略可能改善临床结局并更高效地利用资源。
临床怎么用
- 选择冠心病影像模态时需结合机构资源与临床场景进行经济性考量。
- 可考虑结构化的多模态影像路径以兼顾诊断价值与资源效率。
局限性
- 数据异质性大,尚无法对每种影像模态得出确定性成本效益结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular diseases (CVDs) remain among the leading causes of both health and economic burdens worldwide. Myocardial Perfusion Imaging (MPI) performed using Single Photon Emission Computed Tomography (SPECT) or, more recently, Positron Emission Tomography (PET), has long served as a cornerstone in the diagnosis and management of coronary heart disease (CHD). However, rising healthcare costs and rapidly advancing imaging technologies have prompted re-evaluation of nuclear cardiology's cost-effectiveness, making careful selection of imaging modalities essential. In this review, an economic evaluation of imaging in CHD has been undertaken, summarizing the most relevant studies on the cost-effectiveness of various imaging modalities. The heterogeneity in data - largely related to institutional resources, operator expertise, clinical setting (inpatient vs. outpatient), healthcare system, and reimbursement structure - does not yet allow definitive conclusions on the cost-effectiveness of each individual modality. Therefore, a well-structured multimodality imaging approach appears to provide greater diagnostic and economic value, offering both improved clinical outcomes and more efficient resource utilization.
引用
- Milan E, Giubbini R, Vitola J, et al. Cost-effectiveness of imaging modalities in coronary heart disease: A comprehensive review. Semin Nucl Med. 2026. PMID: 42409703. doi:10.1053/j.semnuclmed.2026.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。